Genesystem Co (XKRX:363250) Gross-Profit-to-Asset % : -2.01% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Genesystem Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Genesystem Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was ₩-759.0 Mil. Genesystem Co's average Total Assets over the quarter that ended in Mar. 2024 was ₩37,755.5 Mil. Therefore, Genesystem Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was -2.01%.

Genesystem Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Genesystem Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genesystem Co Gross-Profit-to-Asset % Chart

Genesystem Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

15.48

85.77

24.91

2.54

-3.96

Genesystem Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial											-2.61	-3.08	-4.12	-7.09	-2.01

Competitive Comparison of Genesystem Co's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Genesystem Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genesystem Co's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genesystem Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Genesystem Co's Gross-Profit-to-Asset % falls into.

Genesystem Co Gross-Profit-to-Asset % Calculation

Genesystem Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	-1586.08	/	( (41183.104	+	38927.991)	/ 2 )
	=	-1586.08	/	40055.5475
	=	-3.96 %

Genesystem Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-758.98	/	( (38927.991	+	36583.079)	/ 2 )
	=	-758.98	/	37755.535
	=	-2.01 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Genesystem Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Genesystem Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genesystem Co (XKRX:363250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200-9, Techno 2-ro, Yuseong-gu, Daejeon, KOR, 34028

Website

http://www.genesystem.co.kr

Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.

Genesystem Co (XKRX:363250) Headlines

No Headlines